Evidence map›Paper›PMID 31213802›Full record

ArticleInternational journal of nanomedicine2019

Sustained delivery of a camptothecin prodrug - CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity.

Dong Dong, Cheng-Hui Hsiao, Beppino C Giovanella, Yifei Wang, Diana Sl Chow, Zhijie Li

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Charge reversal nano-systems for tumor therapy.Journal of nanobiotechnology · 2022
    Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dong DongInternational Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China.
Cheng-Hui HsiaoDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA.
Beppino C GiovanellaCHRISTUS Stehlin Foundation for Cancer Research, Houston, TX, USA.
Yifei WangGuangZhou (Jinan) Biomedical Research and Development Center Co. Ltd, Guangzhou, China.
Diana Sl ChowDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA.
Zhijie LiInternational Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China.

Funding

FOXA1 inhibitors to overcome endocrine resistance in ER+ breast cancerP20CA221731 · NCI · UNIVERSITY OF HOUSTON · PI CHOW, DIANA S-L. · 2018 to 2021
$1.1M
NCI NIH HHS P20 CA221731
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsBody WeightCamptothecinCell ProliferationDelayed-Action PreparationsDrug LiberationHumansKaplan-Meier EstimateMaleMice, NudeNanoparticlesParticle SizeProdrugsSuspensionsTissue DistributionAntineoplastic AgentsCamptothecincamptothecin, C20-propionate esterDelayed-Action PreparationsProdrugsSuspensionsTopoisomerase I InhibitorsanticancercamptothecinCZ48nanosuspensionsustained drug delivery

Identifiers

PMID31213802
PMCPMC6540077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.